Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Roche”

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple SclerosisCompleted
NCT01412333Phase 3Updated Mar 8, 2024
Sponsor: Hoffmann-La Roche
Relapsing Multiple Sclerosis
United States, Argentina, Belarus, Belgium, Bosnia and Herzegovina +19 more
A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)Completed
NCT02913456N/AUpdated Mar 6, 2024
Sponsor: Hoffmann-La Roche
Breast Cancer
Austria, Bulgaria, Italy, Portugal, Romania
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast CancerActive Not Recruiting
NCT03595592Phase 3Updated Mar 6, 2024
Sponsor: Fondazione Michelangelo
Invasive Breast Cancer
Austria, Germany, Italy, Spain
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)Completed
NCT01120184Phase 3Updated Mar 4, 2024
Sponsor: Hoffmann-La Roche
Breast Cancer
United States, Argentina, Australia, Austria, Belgium +33 more
A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid TumorsTerminated
NCT04158583Phase 1Updated Mar 4, 2024
Sponsor: Hoffmann-La Roche
Solid Tumors
Australia, Belgium, Canada, Denmark, Spain
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple SclerosisCompleted
NCT01247324Phase 3Updated Mar 4, 2024
Sponsor: Hoffmann-La Roche
Relapsing Multiple Sclerosis
United States, Argentina, Australia, Austria, Belgium +27 more
Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial)Completed
NCT03976518Phase 2Updated Mar 1, 2024
Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica
Non-Small Cell Lung Cancer
Italy
A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's DiseaseCompleted
NCT03761849Phase 3Updated Mar 1, 2024
Sponsor: Hoffmann-La Roche
Huntingtons Disease
United States, Argentina, Australia, Austria, Canada +13 more
Angelman Syndrome Natural History Study-FAST UKUnknown
NCT05100810N/AUpdated Feb 28, 2024
Sponsor: University of Oxford
Angelman Syndrome
United Kingdom
PriskA Pilot StudyCompleted
NCT05785507N/AUpdated Feb 28, 2024
Sponsor: Erasmus Medical Center
Polycystic Ovary Syndrome
Netherlands
PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)Terminated
NCT03357224Phase 2Updated Feb 22, 2024
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma, T-Cell, Cutaneous · Mycosis Fungoides/Sezary Syndrome
Spain, Switzerland
Human Epidermal Growth Factor Receptor 2 (HER2) Positive Unresectable Locally Advanced or Metastatic Breast Cancer Disease Registry StudyCompleted
NCT02393924N/AUpdated Feb 21, 2024
Sponsor: Hoffmann-La Roche
Breast Cancer
United Kingdom
Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC)Terminated
NCT03943550Phase 1Updated Feb 15, 2024
Sponsor: Hoffmann-La Roche
Ulcerative Colitis
United States, Georgia, Hungary, Moldova, Ukraine
Biomarkers in Patients With Suspected HFpEFRecruiting
NCT06101693N/AUpdated Feb 13, 2024
Sponsor: NHS Greater Glasgow and Clyde
Heart Failure · Obesity · Heart Failure With Preserved Ejection Fraction
United Kingdom
A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531Completed
NCT02956850Phase 1Updated Feb 8, 2024
Sponsor: Hoffmann-La Roche
Hepatitis B, Chronic
Bulgaria, Hong Kong, Italy, Netherlands, New Zealand +3 more
Assessment of the Neuro-glio-epithelial Unit (NGEU) in Biopsies Taken During Peroral Endoscopic Myotomy (POEM) for Achalasia: a Feasibility and Safety Study.Completed
NCT04112693NAUpdated Feb 7, 2024
Sponsor: Nantes University Hospital
Esophageal Achalasia
France
A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid TumorsCompleted
NCT04857138Phase 1Updated Feb 5, 2024
Sponsor: Hoffmann-La Roche
Solid Tumors
Denmark, France, South Korea, Spain, United Kingdom
Treatment of Colorectal Liver Metastases With Immunotherapy and BevacizumabCompleted
NCT03698461Phase 2Updated Jan 31, 2024
Sponsor: Asan Medical Center
Colorectal Neoplasms · Neoplasm Metastasis · Colonic Neoplasms · Rectal Neoplasms
South Korea
Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)Active Not Recruiting
NCT02840409Phase 2Updated Jan 31, 2024
Sponsor: The Hospital for Sick Children
Low Grade Glioma
United States, Australia, Canada, New Zealand
Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid PharmacotherapyCompleted
NCT01120795Phase 4Updated Jan 30, 2024
Sponsor: Melbourne Health
Chronic Hepatitis C
Australia
Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)Terminated
NCT03444870Phase 3Updated Jan 30, 2024
Sponsor: Hoffmann-La Roche
Alzheimer Disease
United States, Australia, Brazil, Canada, China +10 more
A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)Completed
NCT03301883Phase 4Updated Jan 30, 2024
Sponsor: Hoffmann-La Roche
Juvenile Idiopathic Arthritis
China
The Drug Rediscovery Protocol (DRUP Trial)Recruiting
NCT02925234Phase 2Updated Jan 24, 2024
Sponsor: The Netherlands Cancer Institute
Cancer · Tumors · Neoplasm · Neoplasia
Netherlands
A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple SclerosisWithdrawn
NCT05208840Phase 4Updated Jan 23, 2024
Sponsor: Hoffmann-La Roche
Multiple Sclerosis
Russia
A Study to Investigate the Pharmacokinetics of RO7223280 in Critically Ill Participants With Bacterial InfectionsCompleted
NCT05614895Phase 1Updated Jan 22, 2024
Sponsor: Hoffmann-La Roche
Bacterial Infections
United States, France, Israel, Moldova, South Korea

Previous page Next page